Josh Meyer, Sonic AI

Skip to content

Home Discover Library Ask Sonic Projects

Use with Claude or ChatGPT

Home Discover Library Ask Sonic Projects

Use with Claude or ChatGPT

Josh Meyer, Sonic AI

Home/Library/Josh Meyer

J

Josh Meyer

CEO, Chai Discovery · Person · Business

18

Mentions

2

Episodes

18

Claims

Josh Meyer - CEO, Chai Discovery. Tracked across 18 mentions in podcasts and expert conversations analyzed by Sonic.

What Josh Meyer has said

Chai Discovery's Chai-1 is a structure prediction model, while Chai-2 is a generative model for de novo molecule design.

neutral·Joshua Meyer

Chai Discovery released its Chai-1 model, an "atomic level microscope" for predicting molecular interactions, as open source in late 2023.

bullish·Joshua Meyer

In one instance, a Chai Discovery AI model solved a drug discovery problem in two weeks that another company had spent $5-10 million working on.

bullish·Joshua Meyer

Chai Discovery's Chai-1 is a structure prediction model, while Chai-2 is a generative model for de novo molecule design.

Expert perspectiveJoshua MeyerApr 3

Chai Discovery released its Chai-1 model, an "atomic level microscope" for predicting molecular interactions, as open source in late 2023.

Expert perspectiveJoshua MeyerApr 3

In one instance, a Chai Discovery AI model solved a drug discovery problem in two weeks that another company had spent $5-10 million working on.

Expert perspectiveJoshua MeyerApr 3

Chai Discovery believed that the adoption of diffusion models, which can sample multiple distinct hypotheses instead of averaging them, would be a key driver for improving performance in protein struc...

Expert perspectiveJoshua MeyerApr 3

AI models for biology have advanced from predicting the structure of single proteins, as seen with models like AlphaFold, to predicting the structure of entire macromolecular complexes, including prot...

Expert perspectiveJoshua MeyerApr 3

Predicting the 3D structures of DNA and RNA interactions is currently more difficult for AI models than predicting protein and small molecule interactions, potentially due to a lack of training data.

Expert perspectiveJoshua MeyerApr 3

Chai Discovery's internal goal for its molecule design model was a 1% success rate for the year, a benchmark they considered transformative for the field.

Expert perspectiveJoshua MeyerApr 3

A "third wave" of AI-bio companies, including Chai Discovery, has emerged in the last few years, characterized by leveraging recent advances from NLP and computer vision.

Expert perspectiveJoshua MeyerApr 3

The FDA has indicated it will use AI to review regulatory documents submitted by pharmaceutical companies.

Expert perspectiveJoshua MeyerApr 3

Joshua Meyer believes that focusing on increasing the probability of success for drug candidates, as highlighted by Eroom's Law, is the wrong metric for the pharmaceutical industry.

Expert perspectiveJoshua MeyerApr 3

To validate its results, Chai Discovery tested its Chai-2 model across 50 different biological targets, a scale approximately 10 times larger than typical AI biology validation projects.

Expert perspectiveJoshua MeyerApr 3

Chai Discovery's Chai-1 model is an "all-atom" model capable of predicting interactions across different therapeutic modalities, including small molecules and proteins.

Expert perspectiveJoshua MeyerApr 3

Joshua Meyer predicts a future capability where AI models can generate "zero-shot" drug candidates, where a molecule from the first designed batch is viable for clinical trials.

SpeculativeJoshua MeyerApr 3

To ensure generalization, Chai Discovery's model evaluation excluded any targets that had more than 70% sequence identity with the training data.

Expert perspectiveJosh MeyerMar 31

Chai Discovery's first model, Chai 1, was open-sourced and is now being applied throughout the industry.

Expert perspectiveJosh MeyerMar 31

The release of AlphaFold 2 around 2020, which enabled the prediction of single protein structures with experimental accuracy, was a key breakthrough for AI-driven drug discovery.

Expert perspectiveJosh MeyerMar 31

The Chai 2 model maintained a consistent success rate even when tested on targets with as low as 25% sequence similarity to its training data, indicating strong generalization capabilities.

Expert perspectiveJosh MeyerMar 31

Chai Discovery's research paper on Chai 2 evaluated the model on over 50 targets, a significant increase from the one to three targets typically seen in other AI drug discovery papers.

Expert perspectiveJosh MeyerMar 31

Create a free account to see Josh Meyer's full intelligence report - every claim, the relationship network, and AI Q&A across all sources. No card needed.

Get started free

Back to Entities Entity Detail